Interpreting the Results

Making the active surveillance decision for very low, low-, and favorable intermediate-risk patients

The Oncotype DX GPS report for clinically lower risk patients provides actionable data that predicts tumor aggressiveness to help inform the critical treatment decision between active surveillance and immediate treatment.1-4

GPS wedge

Deciding on treatment modality for unfavorable intermediate- and high-risk patients

The tailored Oncotype DX GPS report for clinically higher risk patients provides information that predicts the likelihood of adverse outcomes. This can offer clarity on treatment intensity and help determine the optimal type and extent of treatment with confidence.1-5

GPS distribution curve

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report, and view sample reports .


How do you use the GPS report? The value of the GPS assay.

Dr. Scott Sellinger (Advanced Urology Institute) describes how and why he uses the GPS report in his practice.


Active Surveillance vs Treatment

Active Surveillance vs Treatment case study


Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Exact Sciences Laboratory. You can access the results through the online physician portal or receive the report by fax.

View Sample Reports

Start Report Guide
Start Report Guide
Start Report Guide

  1. Van Den Eeden et al. Eur Urol. 2017.
  2. Klein et al. Eur Urol. 2014.
  3. Cullen et al. Eur Urol. 2014.
  4. Cullen et al. Urology. 2020.
  5. Data on file.

*Adverse pathology defined as Gleason ≥4+3 and/or pT3+.
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Making cancer care smarter.™